Eli Lilly Other Non-Current Liabilities 2010-2024 | LLY
Eli Lilly other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Eli Lilly other non-current liabilities for the quarter ending September 30, 2024 were $6.118B, a 13.84% increase year-over-year.
- Eli Lilly other non-current liabilities for 2023 were $6.09B, a 10.05% increase from 2022.
- Eli Lilly other non-current liabilities for 2022 were $5.534B, a 0.55% decline from 2021.
- Eli Lilly other non-current liabilities for 2021 were $5.564B, a 0.34% increase from 2020.
Eli Lilly Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$6,090 |
| 2022 |
$5,534 |
| 2021 |
$5,564 |
| 2020 |
$5,545 |
| 2019 |
$5,108 |
| 2018 |
$5,058 |
| 2017 |
$5,323 |
| 2016 |
$2,917 |
| 2015 |
$2,616 |
| 2014 |
$3,283 |
| 2013 |
$2,942 |
| 2012 |
$2,704 |
| 2011 |
$2,660 |
| 2010 |
$3,004 |
| 2009 |
$2,398 |
Eli Lilly Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$6,118 |
| 2024-06-30 |
$5,967 |
| 2024-03-31 |
$6,460 |
| 2023-12-31 |
$6,090 |
| 2023-09-30 |
$5,374 |
| 2023-06-30 |
$5,283 |
| 2023-03-31 |
$5,665 |
| 2022-12-31 |
$5,534 |
| 2022-09-30 |
$5,495 |
| 2022-06-30 |
$5,341 |
| 2022-03-31 |
$5,692 |
| 2021-12-31 |
$5,564 |
| 2021-09-30 |
$5,517 |
| 2021-06-30 |
$5,540 |
| 2021-03-31 |
$5,655 |
| 2020-12-31 |
$5,545 |
| 2020-09-30 |
$5,095 |
| 2020-06-30 |
$5,204 |
| 2020-03-31 |
$5,495 |
| 2019-12-31 |
$5,108 |
| 2019-09-30 |
$4,627 |
| 2019-06-30 |
$4,629 |
| 2019-03-31 |
$4,930 |
| 2018-12-31 |
$5,058 |
| 2018-09-30 |
$5,288 |
| 2018-06-30 |
$5,092 |
| 2018-03-31 |
$5,322 |
| 2017-12-31 |
$5,323 |
| 2017-09-30 |
$2,999 |
| 2017-06-30 |
$3,149 |
| 2017-03-31 |
$2,979 |
| 2016-12-31 |
$2,917 |
| 2016-09-30 |
$2,917 |
| 2016-06-30 |
$2,712 |
| 2016-03-31 |
$2,737 |
| 2015-12-31 |
$2,616 |
| 2015-09-30 |
$2,333 |
| 2015-06-30 |
$2,481 |
| 2015-03-31 |
$2,428 |
| 2014-12-31 |
$3,283 |
| 2014-09-30 |
$2,575 |
| 2014-06-30 |
$2,777 |
| 2014-03-31 |
$2,968 |
| 2013-12-31 |
$2,942 |
| 2013-09-30 |
$2,122 |
| 2013-06-30 |
$2,669 |
| 2013-03-31 |
$2,659 |
| 2012-12-31 |
$2,704 |
| 2012-09-30 |
$3,090 |
| 2012-06-30 |
$2,680 |
| 2012-03-31 |
$2,692 |
| 2011-12-31 |
$2,660 |
| 2011-09-30 |
$2,508 |
| 2011-06-30 |
$2,833 |
| 2011-03-31 |
$3,111 |
| 2010-12-31 |
$3,004 |
| 2010-09-30 |
$2,517 |
| 2010-06-30 |
$2,338 |
| 2010-03-31 |
$2,311 |
| 2009-12-31 |
$2,398 |
| 2009-09-30 |
$2,275 |
| 2009-06-30 |
$2,301 |
| 2009-03-31 |
$2,263 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$789.394B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
